Biopeople

Science advisors

Science advisors

03.07.2014 - British Ario Pharma Ltd has strengthened its scientific capacities by adding two research experts to its team.

The Cambridge-based respiratory disease specialist has appointed Peter Barnes and Wisia Wedzichato its Scientific Advisory Board. The current President of the European Respiratory Society, Barnes has published more than 1,000 peer-review papers on asthma and chronic obstructive pulmonary disease (COPD). The most highly-cited respiratory researcher in the world over the last 20 years also co-founded RespiVert (now Johnson & Johnson). Wedzicha is a member of the Guideline Development Group for the revision of the NICE COPD guidelines, and has a particular interest in the causes, mechanisms, impact and prevention of COPD exacerbations and the role bacterial and viral infections play in them. She directs an active research group in that area and has published extensively on the topic.

18.01.2014 Former Novartis CMO, Dr. Markus Weissbach, takes over the newly created key division Registration and Clinical Development at CytoTools AG. With the new appointment, CytoTools extends its managerial board to three persons.

CytoTools

Weissbach moved from the supervisory board to the management board of CytoTools AG, a technology holding company with participations in the field of pharmaceuticals and other medical products. He previously held a series of managerial positions with clinical contract research companies and in research and clinical development at large pharmaceutical companies. Among other posts, he was Chief Medical Officer at Novartis Vaccines & Diagnostics, Chairman of the Board at Aptiv Solutions, President of ICON Europe and a director at Takeda Pharmaceuticals and Knoll AG.

14.01.2014 Olivier Brandicourt has been appointed Chairman of the Board of Management of Bayer HealthCare and member of the Bayer AG Executive Council.

Bayer AG

He will replace Professor Wolfgang Plischke, who has led Bayer HealthCare on an interim basis in addition to his existing duties as a Bayer AG Board Member since March 2013. Brandicourt has 25 years of experience in the pharmaceutical industry, including executive responsibilities in France, the US, Canada and the UK. Over the last three years, he has been a member of the Executive Leadership Team of Pfizer Inc. in New York. Brandicourt is an Honorary Fellow of the Royal College of Physicians in London, UK.

13.01.2014 Oxford Gene Technology Ltd. (OGT) has appointed Dr. Bob Holland as Chief Medical Officer.

Dr. Holland is an expert in biomarker-driven drug development and has more than 25 years of experience in the pharmaceutical industry. Dr. Holland worked as vice president at AstraZeneca plc and was the head of AZ’s Personalised Healthcare and Biomarkers division. In this position, he generated a pipeline of 14 developmental drug programmes that were matched with potential companion diagnostic tests. With Holland’s appointment as CMO, OGT is aiming to strengthen its focus on cancer biomarkers.

09.01.2014 The European Food Safety Authority (EFSA) has appointed Dr. Bernhard Url as its new Acting Executive Director.

EFSA

Before he joined EFSA in 2012 as Director of Risk Assessment and Scientific Assistance, Dr. Url was marketing director at the Austrian Agency for Health and Food Safety for nearly ten years. From 2008 to March 2012, Dr. Url also served as a member of EFSA’s Management Board. After acting as Deputising Executive Director since July, he will now carry out the role of Acting Executive Director until a permanent appointment is made.

19.12.2013 EuropaBio’s Secretary General Nathalie Moll has been given the ”2013 Women Innovation” prize at the Women & Technologies conference in Milan.

She got the award for raising awareness about the role of bio­technology in increasing sustainability for future generations.The biochemist, who has been with EuropaBio for over 10 years, has also worked in the biotech and food policy area for the European Crop Protection Association, as well as for the Italian national biotech association Assobiotec. The Technovisionaries award publicly recognises women who have demonstrated an ability to combine creativity and innovation in order to improve quality of life, in particular in the area of food and nutrition. "Women have shown an increased commitment in using new technologies while also making progress in developing technology and promoting innovation", declared Gianna Martinengo, founder and chairwoman of the conference.

Photo: EuropaBio

16.12.2013 Désiré Collen, founder of ThromboGenics, was given the Scrip Lifetime Achievement Award at the end of November in London for his outstanding contributions to the pharmaceutical/biotech industry.

Collen played a key role in the development of both tissue plasminogen activator (tPA) for acute myocardial infarction and ischemic stroke, and ocriplasmin for the treatment of symptomatic vitreomacular adhesion/vitreomacular traction. A treatment for acute myocardial infarctions, tPA was a key product in Genentech’s success in the late 1980s and 1990s. Ocriplasmin, a proteolytic enzyme indicated for the treatment of symptomatic vitreo­macular adhesion, was launched in 2013 under the trade name Jetrea, and licensed by Alcon in March 2012 in a a375m deal. Collen has co-authored more than 650 scientific publications, and is listed as co-inventor on 20 patents and patent applications.

 Photo: VIB

12.12.2013 Jacqueline Lecourtier has joined industrial biotech specialist Deinove S.A. (Paris) as the new President of the firm's Scientific Advisory Board.

Lecourtier comes in from the French National Research Agency, where she was General Manager from 2006-2012. Prior to that, she was Scientific Director at the French Institute of Petroleum (IFP). Lecourtier is an engineer from the École Nationale Supérieure des Industries Chimiques, and she also holds a doctorate in physics. At the beginning of her career Lecourtier was a researcher at the CNRS (Conseil national de la recherche scientifique – French National Research Council), and received international recognition for many research projects that she conducted and directed.

Photo: Jaques Le Goff

10.12.2013 Novasep SA has named Nadege Laborde President of its Industrial Bio­tech Business Unit.

The new member of the executive committee is expected to expand Novasep’s market reach into new geo­graphical territories. Laborde joined Novasep in 2000 after qualifying as an engineer from the École Centrale (Paris). Starting as a project manager, she rapidly expanded her responsibilities, quickly taking on roles as engineering manager in the US and Asia, and later becoming head of the system engineering and construction department.

Photo: Novasep SA

06.12.2013 French biotech TxCell SA appointed Damian Marron as Chief Executive Officer at the beginning of November to push the development of its Phase II antigen specific Treg cell immuno­therapy Ovasave.

The new CEO, who brings in extensive experience in licensing deals, comes from Cytheris SA, a specialist for IL-7-based immunotherapies. From 2008-2012 Marron served as CEO of Trophos SA. Prior to that he was Executive Vice President Corporate Development at NicOx SA. In the past, he has held business development and operational roles at 3M Pharmaceuticals, Orphan Europe, Rhone-Poulenc-Rorer and GlaxoSmithKline. In addition, François Meyer, previously CEO and Chairman of the Board of TxCell has been appointed Executive Chairman of the Board of Directors.

Photo: TxCell

04.12.2013 The International Diabetes Federation (IDF) has appointed Dr. Petra Wilson as its new CEO. She joins IDF from Cisco, where she was Senior Director of its European Health and Care Business Solutions team.

Wilson has previously held posts as Director of the European Health Management Association and as a science officer for the European Commission. She is also a former senior lecturer in law at the University of Nottingham, where she taught in both the law and medical schools. Wilson is British born and lives in Brussels. She will continue her roles as Honorary Reader at the Centre for Health Informatics and Multiprofessional Education at University College London, and as a Non-Executive Director of the Digital Health Institute in Scottland.

Photo: International Diabetes Federation

Vorherige Seite5/19Nächste Seite

Stock list

All quotes

TOP

  • FLAMEL TECHNOLOGIES (F)14.70 USD11.28%
  • SERODUS (N)3.05 NOK7.02%
  • ADDEX (CH)4.54 CHF5.83%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.48 EUR-10.04%

TOP

  • SANTHERA (CH)70.65 CHF111.2%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.43 EUR98.1%

FLOP

  • THROMBOGENICS (B)8.67 EUR-51.8%
  • MERCK KGAA (D)63.67 EUR-50.5%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • IXICO (UK)55.50 GBP314.2%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.67 EUR-73.0%

No liability assumed, Date: 10.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events